Use of dehydroepiandrosterone in a patient with infertility and androgen deficiency

1. Ferraretti A.P., La Marca A., Fauser B.C.J.M., Tarlatzis B., Nargund G., Gianaroli L. ESHRE working group on poor ovarian response definition. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 2011; 26(7): 1616-24. https://dx.doi.org/10.1093/humrep/der092.
2. Goverde A.J., McDonnell J., Schats R., Vermeiden J.P.W., Homburg R., Lambalk C.B. Ovarian response to standard gonadotrophin stimulation for IVF is decreased not only in older but also in younger women in couples with idiopathic and male subfertility. Hum. Reprod. 2005; 20(6): 1573-7. https://dx.doi.org/10.1093/humrep/deh827.
3. Bosdou J.K., Venetis C.A., Kolibianakis E.M., Toulis K.A., Goulis D.G., Zepiridis L. et al. The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update. 2012; 18(2): 127-45. https://dx.doi.org/10.1093/humupd/dmr051.
4. Kyrou D., Kolibianakis E.M., Venetis C.A., Papanikolaou E.G., Bontis J., Tarlatzis B.C. How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Fertil. Steril. 2009; 91(3): 749-66. https://dx.doi.org/10.1016/j.fertnstert.2007.12.077.
5. Крстич Е.В., Краснопольская К.В., Кабанова Д.И. Новые подходы к повышению эффективности ЭКО у женщин старшего репродуктивного возраста. Акушерство и гинекология. 2010; 2: 48-53. [Krstich E.V., Krasnopolskaya K.V., Kabanova D.I. New approaches to improving the effectiveness of IVF in older women of reproductive age. Obstetrics and gynecology. 2010; 2: 48-53. (in Russian)].
6. Gleicher N., Barad D.H. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR). Reprod. Biol. Endocrinol. 2011; 9: 67. https://dx.doi.org/10.1186/1477-7827-9-67.
7. Doan H.T., Quan L.H., Nguyen T.T. The effectiveness of transdermal testosterone Gel 1% (Androgel) for poor responders undergoing in vitro fertilization. Gynecol. Endocrinol. 2017; 33(12): 977-9. https://dx.doi.org/10.1080/09513590.2017.1332586.
8. Horie K., Takakura K., Fujiwara H., Suginami H., Liao S., Mori T. Immunohistochemical localization of androgen receptor in the human ovary throughout the menstrual cycle in relation to oestrogen and progesterone receptor expression. Hum. Reprod. 1992; 7(2): 184-90. https://dx.doi.org/10.1093/oxfordjournals.humrep.a137614.
9. Garcia-Velasco J.A., Moreno L., Pacheco A., Guillén A., Duque L., Requena A. et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil. Steril. 2005; 84(1): 82-7. https://dx.doi.org/10.1016/j.fertnstert.2005.01.117.
10. Nielsen M.E., Rasmussen I.A., Kristensen S.G., Christensen S.T., Møllgård K., Andersen E.W. et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol. Hum. Reprod. 2011; 17(1): 63-70. https://dx.doi.org/10.1093/molehr/gaq073.
11. Fouany M.R., Sharara F.I. Is there a role for DHEA supplementation in women with diminished ovarian reserve? J. Assist. Reprod. Genet. 2013; 30(9): 1239-44. https://dx.doi.org/10.1007/s10815-013-0018-x.
12. Nagels H.E., Rishworth J.R., Siristatidis C.S., Kroon B. Androgens (dehydroepiandrosterone or testosterone) for women undergoing assisted reproduction. Cochrane Database Syst. Rev. 2015; (11): CD009749. https://dx.doi.org/10.1002/14651858.CD009749.pub2.
13. Siristatidis C., Lykakis A., Chrelias C. Proficiency in oocyte retrieval: plausible steps before perfection. Fertil. Steril. 2011; 96(5): e161; author reply e162. https://dx.doi.org/10.1016/j.fertnstert.2011.08.030.
14. Zhang Y., Zhang C., Shu J., Guo J., Chang H.M., Leung P.C.K. et al. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. Hum. Reprod. Update. 2020; 26(2): 247-63. https://dx.doi.org/10.1093/humupd/dmz046.
15. Genazzani A.D., Stomati M., Strucchi C., Puccetti S., Luisi S., Genazzani A.R. Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone‐releasing hormone‐induced growth hormone and insulin‐like growth factor‐1 secretion in early and late postmenopausal women. Fertil. Steril. 2001; 76(2): 241‐8. https://dx.doi.org/10.1016/s0015-0282(01)01902-1.
16. Artini P.G., Simi G., Ruggiero M., Pinelli S., Di Berardino O.M., Papini F. et al. DHEA supplementation improves follicular microenviroment in poor responder patients. Gynecol. Endocrinol. 2012; 28(9): 669-73. https://dx.doi.org/ 10.3109/09513590.2012.705386.
17. Nguyen T.V., McCracken J.T., Ducharme S., Cropp B.F., Botteron K.N., Evans A.C. et al. Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development. J. Neurosci. 2013; 33(26): 10840-8. https://dx.doi.org/10.1523/JNEUROSCI.5747-12.2013.
18. Kara M., Aydin T., Aran T., Turktekin N., Ozdemir B. Does dehydroepiandrosterone supplementation really affect IVF-ICSI outcome in women with poor ovarian reserve? Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 173: 63-5. https://dx.doi.org/10.1016/j.ejogrb.2013.11.008.
19. Moawad A.R., Fisher P., Zhu J., Choi I., Polgar Z., Dinnyes A. et al. In vitro fertilization of ovine oocytes vitrified by solid surface vitrification at germinal vesicle stage. Cryobiology. 2012; 65(2): 139-44. https://dx.doi.org/10.1016/j.cryobiol.2012.04.008.
20. Tartagni M., De Pergola G., Damiani G.R., Pellegrino A., Baldini D., Tartagni M.V. et al. Potential benefit of dehydroepiandrosterone supplementation for infertile but not poor responder patients in a IVF program. Minerva Ginecol. 2015; 67(1): 7-12.
21. Tartagni M., Cicinelli M.V., Baldini D., Tartagni M.V., Alrasheed H., DeSalvia M.A. et al. Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old. Reprod. Biol. Endocrinol. 2015; 13: 18. https://dx.doi.org/10.1186/s12958-015-0014-3.
22. Wiser A., Gonen O., Ghetler Y., Shavit T., Berkovitz A., Shulman A. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum. Reprod. 2010; 25(10): 2496-500. https://dx.doi.org/10.1093/humrep/deq220.
23. Yeung T.W.Y., Li R.H.W., Lee V.C.Y., Ho P.C., Ng E.H.Y. A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 2013; 98(1): 380-8. https://dx.doi.org/10.1210/jc.2012-3071.
24. Yeung T.W.Y., Chai J., Li R.H.W., Lee V.C.Y., Ho P.C., Ng E.H.Y. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil. Steril. 2014; 102(1): 108-15. e1. https://dx.doi.org/10.1016/j.fertnstert.2014.03.044.
25. Zhang H.H., Xu P.Y., Wu J., Zou W.W., Xu X.M., Cao X.Y. et al. Dehydroepiandrosterone improves follicular fluid bone morphogenetic protein-15 and accumulated embryo score of infertility patients with diminished ovarian reserve undergoing in vitro fertilization: a randomized controlled trial. J. Ovarian Res. 2014; 7: 93. https://dx.doi.org/10.1186/s13048-014-0093-3.
26. Kotb M.M., Hassan A.M., AwadAllah A.M. Does dehydroepiandrosterone improve pregnancy rate in women undergoing IVF/ICSI with expected poor ovarian response according to the Bologna criteria? A randomized controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2016; 200: 11-5. https://dx.doi.org/ 10.1016/j.ejogrb.2016.02.009.

Received 30.06.2020

Accepted 10.10.2020